COVID-19 Vaccination as a Potential Trigger for New-Onset Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Vaccinology

Background:

• Immune hyperactivation is a known, albeit rare, potential side effect associated with various vaccines.
• The COVID-19 pandemic spurred rapid vaccine development, necessitating ongoing monitoring for adverse events.

Observation:

• A 54-year-old male presented with flu-like symptoms two weeks post-second COVID-19 vaccine dose.
• Clinical findings included fever, cervical lymphadenopathy, and purpuric lesions on the feet.
• Laboratory results revealed hypocomplementemia and high titers of various autoantibodies, including ANA, anti-dsDNA, and anti-Smith.

Findings:

• The patient was diagnosed with new-onset systemic lupus erythematosus (SLE).
• Autoimmune markers strongly indicated SLE, with a negative workup for malignancy and infection.
• Treatment with high-dose steroids resulted in a positive clinical response.

Implications:

• This case suggests a potential association between COVID-19 vaccination and the rare development of SLE.
• Further research is warranted to understand the immunological mechanisms and incidence of such rare vaccine-related adverse events.
• Clinicians should consider SLE in the differential diagnosis for patients presenting with relevant symptoms post-COVID-19 immunization.